NasdaqGM - Nasdaq Real Time Price USD

Vericel Corporation (VCEL)

Compare

59.25

+0.27

+(0.46%)

At close: January 30 at 4:00:01 PM EST

58.81

-0.44

(-0.74%)

After hours: 7:59:15 PM EST

Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets

Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest Quarterly MACI Implants, Surgeons, and Biopsies Since Launch and Strong Early MACI Arthro Launch Indicators Record Fourth Quarter Gross Margin of Approximately 77% and Adjusted EBITDA Margin of 39% 2025 Total Revenue Guidance of 20% to 23% Growth Mid-Term Profitability Targets Increased to Gross Margin

GlobeNewswire 16 days ago

VCEL
+0.46%
High Growth Tech Stocks To Watch In January 2025

Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and expansion while aligning with broader positive market trends.

Simply Wall St. 16 days ago

EXAS

VCEL
+0.46%
SEMR
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Cor

GlobeNewswire 22 days ago

VCEL
+0.46%
Vericel price target raised to $67 from $61 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Vericel (VCEL) to $67 from $61 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, s

TipRanks last month

VCEL
+0.46%
High Growth Tech Stocks to Watch in December 2024

Over the last 7 days, the United States market has remained flat, but it has risen by an impressive 28% over the past year, with earnings projected to grow by 15% annually in the coming years. In this environment, high growth tech stocks that demonstrate strong revenue potential and innovative capabilities are particularly noteworthy for investors seeking opportunities in a dynamic sector.

Simply Wall St. last month

ENFN

GAMB

VCEL
+0.46%
High Growth Tech Stocks To Explore In November 2024

The United States market has experienced a notable upswing, climbing 3.9% over the last week and 33% over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Simply Wall St. 2 months ago

AVPT

AVPTW

OKTA
Vericel Stock Sees RS Rating Shoot Higher

A Relative Strength Rating upgrade for Vericel shows improving technical performance. Will it continue?

Investor's Business Daily 2 months ago

ADMA

VCEL
+0.46%
CPRX
Vericel Third Quarter 2024 Earnings: Beats Expectations

Vericel ( NASDAQ:VCEL ) Third Quarter 2024 Results Key Financial Results Revenue: US$57.9m (up 27% from 3Q 2023). Net...

Simply Wall St. 2 months ago

VCEL
+0.46%
Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ...

Vericel Corp (VCEL) reports a 27% revenue increase and strategic advancements, positioning for sustained growth despite rising expenses.

GuruFocus.com 2 months ago

VCEL
+0.46%
Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates

Vericel (VCEL) delivered earnings and revenue surprises of 60% and 4.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

VCEL
+0.46%
Vericel Reports Third Quarter 2024 Financial Results

Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarte

GlobeNewswire 2 months ago

VCEL
+0.46%
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 3 months ago

PRTA

VCEL
+0.46%
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel w

GlobeNewswire 3 months ago

VCEL
+0.46%
Vericel Corp. (VCEL) Cooled Down in Q3 After a 20% Rise in the First Half

Conestoga Capital Advisors, an asset management company, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. At its September meeting, the Federal Reserve lowered the Federal Funds rate by 50 basis points due to weaker employment growth and moderate inflation. Equity markets welcomed the news, raising optimism for a soft landing in […]

Insider Monkey 3 months ago

VCEL
+0.46%
^RUT
Vericel Corp (VCEL) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ...

Vericel Corp (VCEL) reports strong revenue growth driven by MACI demand, while navigating challenges in the burn care market.

GuruFocus.com 3 months ago

VCEL
+0.46%
High Growth Tech Stocks To Watch In October 2024

As global markets navigate the complexities of escalating Middle East tensions and robust U.S. job growth, investors are closely monitoring the performance of key indices like the S&P 500 and Nasdaq Composite, both showing significant year-to-date gains despite geopolitical uncertainties. In this environment, identifying promising high-growth tech stocks involves looking for companies that demonstrate resilience and adaptability to market shifts, coupled with innovative capabilities that...

Simply Wall St. 3 months ago

VCEL
+0.46%
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024

CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation

GlobeNewswire 4 months ago

VCEL
+0.46%
Exploring Three High Growth Tech Stocks in the United States

Over the last 7 days, the market has remained flat, but it is up 23% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying high growth tech stocks that can capitalize on these trends is crucial for investors seeking robust returns.

Simply Wall St. 5 months ago

NTRA

HALO

VCEL
+0.46%
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro

First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI’s $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding the MACI® (autologous cultu

GlobeNewswire 5 months ago

VCEL
+0.46%
MediWound and Vericel win FDA paediatric label expansion for NexoBrid

The companies’ thermal burn treatment, NexoBrid, has been approved as a non-surgical solution for managing severe burn injuries in both paediatric and adult burn patients.

Medical Device Network 5 months ago

MDWD

VCEL
+0.46%

Performance Overview

Return	VCEL	S&P 500
YTD	+7.14%	+2.78%
1-Year	+32.97%	+23.20%
3-Year	+78.03%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vericel Corporation (VCEL)

Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets

High Growth Tech Stocks To Watch In January 2025

Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Vericel price target raised to $67 from $61 at Truist

High Growth Tech Stocks to Watch in December 2024

High Growth Tech Stocks To Explore In November 2024

Vericel Stock Sees RS Rating Shoot Higher

Vericel Third Quarter 2024 Earnings: Beats Expectations

Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ...

Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates

Vericel Reports Third Quarter 2024 Financial Results

Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?

Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024

Vericel Corp. (VCEL) Cooled Down in Q3 After a 20% Rise in the First Half

Vericel Corp (VCEL) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ...

High Growth Tech Stocks To Watch In October 2024

Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024

Exploring Three High Growth Tech Stocks in the United States

Vericel Announces FDA Approval and Commercial Availability of MACI Arthro

MediWound and Vericel win FDA paediatric label expansion for NexoBrid

Performance Overview